| 摘要: |
| 目的芬吗通连续联合治疗对绝经后女性子宫内膜及乳腺的影响。方法筛选150例绝经后有围绝经期综合征的妇女，按随机数字表法分为芬吗通组和安今益组，各75例。芬吗通组给予芬吗通连续联合治疗法，即1/10芬吗通[复合包装制剂，白片（1mg雌二醇）、灰片（10mg地屈孕酮+1mg雌二醇）],白＋灰各0.5片/d；安今益组给予安今益（复方制剂，每片含雌二醇1mg+屈螺酮2mg），1片/d。两组患者均连续服药1年。观察两组用药后3、6及12个月的非预期阴道流血情况、子宫内膜厚度及乳腺BI-RAD分级情况。结果两组患者治疗3个月芬吗通组非预期阴道流血天数明显低于安今益组，子宫内膜厚度高于安今益组，差异有统计学意义（P＜0.05）。两组患者治疗6、12个月相比，非预期阴道流血天数、子宫内膜厚度无统计学差异（P＞0.05）。两组患者治疗3、6、12个月，乳腺BI-RAD分级无统计学差异（P＞0.05）。结论与安今益比较，芬吗通连续联合治疗绝经后围绝经期综合征的妇女不增加发生子宫内膜厚度及乳腺病变风险。 |
| 关键词: 芬吗通 连续联合治疗 非预期阴道流血 子宫内膜厚度 乳腺分级 |
| DOI：10.12056/j.issn.1006-2785.2018.40.11.2017-3169 |
| 分类号: |
| 基金项目:杭州市科技局项目（20170533B56）；国家卫生和计划生育委员会、科学研究基金，浙江省医疗卫生科技计划（wkj2013-2-024）；浙江省科技厅计划项目（2014C03044-1) |
|
| Effects of continuous combined femonston therapy on endometrium and mammary gland in postmenopausal women |
|
|
|
Hangzhou Municipal Maternity hospital
|
| Abstract: |
| Objective To evaluate the effects of continuous combined femonston therapy on endometrium and mammary
gland in postmenopausal women. Methods One hundred and fifty women with perimenopausal symptoms after menopause attending menopausal clinic of Hangzhou Municipal Gynecology and Obstetrics Hospital were randomly divided into femonston group and Anjinyi group. Patients in femonston group were given femonston therapy (a complex packing with estradiol 1mg and estradiol/dydrogesterone 10mg, Abbott Laboratories, USA) and patients in Anjinyi group were given Anjinyi (combined preparation with estradiol 1mg+drospirenone 2mg, Bayer Pharmaceuticals, Germany). Both groups of patients received continuous medication for 1 year. The unintended vaginal bleeding, endometrial thickness, and breast BI-RAD grading were observed at 3, 6 and 12 months after treatment. Results After 3 months of treatment the duration of unintended vaginal bleeding in femonston group was significantly shorter than that in Anjinyi group and the thickness of the endometrium in femonston was
higher than that of Anjinyi group (both P ＜0.05). There were no significant differences in the duration of unintended vaginal
bleeding and endometrial thickness between the two groups 6 and 12 months after treatment (P ＞0.05). There was no significant difference in BI-RAD classification between two groups at 3, 6 and 12 months (P ＞0.05). Conclusion Postmenopausal women treated with femonston for perimenopausal syndrome may not increase the risk of endometrial and breast lesions. |
| Key words: Femonston Continuous combined therapy Unintended vaginal bleeding Endometrial thickness Mammary gland classification |
